Drug Discovery

The cardiovascular research community stood in stunned silence this week as a once-heralded clinical champion stumbled at the very finish line of its long journey toward regulatory approval. Shares of Ionis Pharmaceuticals plummeted by 21% in early trading, while AstraZeneca faced an 8% drop,

The relentless march of Huntington’s disease continues to challenge the limits of modern medicine, functioning as a genetic ticking clock that remains largely unstopped despite decades of intensive research. This genetic disorder represents one of the most daunting frontiers in neurology because no

The landscape of oncological care has shifted dramatically as researchers seek more precise ways to identify and eradicate malignant cells without damaging the healthy tissue surrounding them. Traditional methods of treating prostate cancer, while effective to an extent, often struggle with the

The pharmaceutical industry has long faced the daunting challenge of reconciling aggressive commercial expansion with the urgent need for environmental stewardship. AstraZeneca has demonstrated that these seemingly conflicting goals can coexist by achieving a sixty-eight percent reduction in

The global battle against tuberculosis has entered a decisive new phase as researchers leverage advanced artificial intelligence to compress decades of traditional pharmaceutical development into a matter of months. Despite being a preventable and curable disease, tuberculosis continues to claim

For more than a century, neurologists have known that the cognitive decay associated with multiple sclerosis stems from damage to the brain’s gray matter, yet these vital areas remained stubbornly invisible on conventional MRI scans until the arrival of sophisticated computational models. The